Compile Data Set for Download or QSAR
Report error Found 58 Enz. Inhib. hit(s) with all data for entry = 11968
TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667099(US20240116947, Example 46 | Methyl 4-[2-({4-[7-(5-...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667089(US20240116947, Example 34 | N-(4-{7-[2-fluoro-5-(p...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667090(US20240116947, Example 35 | 3-{4-[2-({4-[7-(5-chlo...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667091(US20240116947, Example 36 | 3-(4-{2-[bis(2- hydrox...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667092(US20240116947, Example 37 | 3-[4-(2-carbamoylethyl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667093(US20240116947, Example 38 | N-{4-[7-(6-chloro-3-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667094(US20240116947, Example 39 | N-{4-[7-(6-chloro-3-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667095(US20240116947, Example 41 | N-{4-[7-(2-chloro-5-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667096(US20240116947, Example 42 | N-{4-[7-(2-chloro-5-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667097(US20240116947, Example 43 | N-{4-[7-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667098(US20240116947, Example 45 | Methyl 4-[2-({4-[7-(5-...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667069(US20240116947, Example 8 | N-{4-[7-(5-chloro-2-flu...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667100(US20240116947, Example 47 | Methyl 2-{4-[2-({4-[7-...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667101(US20240116947, Example 48 | Methyl 2-{4-[2-({4-[7-...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667102(US20240116947, Example 49 | Methyl 1-[2-({4-[7-(5-...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667103(US20240116947, Example 50 | Methyl 2-{1-[2-({4-[7-...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667104(US20240116947, Example 51 | N-{4-[5-amino-7-(5-chl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667105(US20240116947, Example 52 | N-{4-[7-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667106(US20240116947, Example 53 | N-{4-[7-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667107(US20240116947, Example 54 | N-{4-[7-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667108(US20240116947, Example 55 | 1-(4-(7-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667087(US20240116947, Example 32 | N-{4-[7-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667068(US20240116947, Example 6 | N-{4-[7-(5-chloro-2-flu...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667070(US20240116947, Example 9 | N-{4-[7-(5-chloro-2-flu...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667071(US20240116947, Example 10 | N-{4-[7-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667072(US20240116947, Example 14 | N-{4-[7-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667073(US20240116947, Example 16 | 7-(5-chloro-2-fluoroph...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667074(US20240116947, Example 18 | 3-[bis(2-hydroxyethyl)...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667075(US20240116947, Example 19 | N-{4-[7-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667076(US20240116947, Example 20 | N-{4-[7-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667077(US20240116947, Example 21 | 3-[bis(oxetan-3-yl)ami...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667079(US20240116947, Example 23 | methyl 2-{[2-({4-[7-(5...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667080(US20240116947, Example 24 | N-{4-[7-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667081(US20240116947, Example 25 | N-{4-[7-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667082(US20240116947, Example 26 | N-{4-[7-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667083(US20240116947, Example 28 | N-{4-[7-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667084(US20240116947, Example 29 | N-{4-[7-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667085(US20240116947, Example 30 | N-{4-[7-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667086(US20240116947, Example 31 | 3-{4-[2-({4-[7-(5-chlo...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667088(US20240116947, Example 33 | N-{4-[7-(5-cyclopropyl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667078(US20240116947, Example 22 | N-{4-[7-(5-chloro-2-fl...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667112(US20240116947, Example 15 | 7-(5-chloro-2-fluoroph...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667114(US20240116947, Example 44 | 7-(5-chloro-2-fluoroph...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667113(US20240116947, Example 27 | N-{4-[7-(5-chloro-2-fl...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667111(US20240116947, Example 13 | 4-{7-[2-fluoro-5-(prop...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667110(US20240116947, Example 12 | 4-[7-(5-cyclopropyl-2-...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667109(US20240116947, Example 3 | 4-[7-(5-chloro-2-fluoro...)
Affinity DataIC50: 3nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667169(US20240116947, Example 1 | 4-[7-(5-chloro-2-fluoro...)
Affinity DataIC50: 7.5nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667170(US20240116947, Example 2 | 7-(5-chloro-2-fluorophe...)
Affinity DataIC50: 7.5nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM667172(US20240116947, Example 4 | 4-[7-(2,5-difluoropheny...)
Affinity DataIC50: 7.5nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 58 total ) | Next | Last >>
Jump to: